reason report
live ada time-in-rang control-iq
bottom line weekend attend american diabet
associ ada annual meet -- one largest global diabet
meet attract endocrinologist diabet nurs educators/
nurs practition efficaci data op control-iq
dclp studi interim data freelif kid ap studi present
dr sue brown dr eric renard studi demonstr
improv time rang mg/dl control-iq control-iq
provid autom correct bolus hybrid closed-loop system
use glucos data dxcm op sensor outcom --
overal time-in-rang low rang -- larg expect
investor still think posit event believ
suffici support fda approv control-iq
compani plan submit regulatori file fda peopl
year old shortli roll later year
fda industri work tirelessli toward develop
mani perceiv ultim gold standard diabet care
artifici pancrea believ well-posit
upcom control-iq launch accuraci clinic outcom
ease-of-us perspect mdt mp pipelin look
compel reiter view diabet devic whole
-- continu glucos monitor pump --
adopt inflect there signific runway growth across
player technolog continu evolv
make good progress pipelin goal view
like remain share gain posit basal-iq continu roll
upcom launch control-iq
control-iq demonstr improv time rang
hypoglycemia prevent slim insulin pump control-
iq technolog util read op sensor predict
glucos level adjust insulin deliveri prevent high low
system also autom correct bolus featur
commerci avail today autom insulin deliveri devic still
allow user manual bolu meal dclp studi control-
iq effect increas time-in-rang mg/dl
control arm reduc time hypoglycemia
control arm encouragingli control-iq demonstr
even greater improv time-in-rang overnight control-iq
work aggress risk hypoglycemia higher
time-in-rang overnight vs control group given
improv achiev control-iq hit statist signific
endpoint believ pivot studi suffici evid
support fda approv interim data patient age year
old freelif kid ap studi demonstr time-in-rang overal
overnight control-iq vs control arm still earli
think posit earli data bode well pediatr indic
expans compani plan submit separ regulatori
file pediatr data upon complet pediatr studi
pleas refer page import disclosur price chart analyst certif
highlight robust pipelin market leader today
pump market share world-wide vs market model estim
outlin robust pipelin diabet solidifi market-
lead posit includ minim product launch
compani target time-in-rang autom meal
heal carb count glucos target vs
dl notabl minim bluetooth enabl
person close loop system compani anticip
fda submiss compani target time-
in-rang plan fda submiss guardian
sensor non-adjunct claim allow coverag
plan fda submiss next-gener sensor
synergi sensor elimin calibr flip side
also announc partnership tidepool essenti
open hardwar architectur use cgm sensor
seem primari issu today seem
capitul could enabl patient integr
sensor mdt pump via tidepool algorithm
physician view follow current ada confer
back tomorrow healthcar practition view
via medacorp meet floor tour
outcom variou compar studi
time rang mg/dl
time rang overnight mg/dl
compani report present late-break session ada american diabet associ annual meet variou clinic public
daniel antalffi certifi view express report accur reflect view part
compens directli relat specif recommend view contain report
rate price target histori inc
leerink place outperform rate octob
creat bluematrix
next month believ share could trade assum share trade
ev/sal estim share current trade sale estim
premium compar smid-cap med-tech compani nxtm
believ continu deliv estim upsid sustain ev/sal multipl current
level ultim believ share warrant least modest premium smid-cap med-tech stock
univers given substanti highli under-penetrated total address market per
estim consist upsid potenti top-tier growth outlook longer term
risk valuat
risk includ failur continu evolv sensor technolog includ verili product type patient
toward sensor-integr pump potenti price pressur increas competit potenti product
recal reimburs issu
rate price target histori medtron plc
leerink place market perform rate jan
creat bluematrix
price target appli price-to-earnings multipl ep estim assum
share sustain current multipl ep estim though believ could
eventu return path consist mid-single-digit top-lin growth -- rtg big piec growth
acceler -- remain sidelin pend clariti cvg sale abil absorb/
move past on-going headwind ramp key pipelin product surgic robot minim
therapi group mitg time less certain see limit multipl expans
mid-single-digit growth trajectori larg predic new product launch sustain trend without
risk
risk valuat
risk valuat includ continu signific spine market spine sale declin market fail regain
deliv product pipelin failur success execut cost save initi
rate price target histori insulet corpor
leerink initi coverag june outperform rate
creat bluematrix
continu rate share op pt appli ev/sal multipl sale
estim share current trade sale estim expect multipl hold
current level given believ sustain double-digit growth next year dramat
improv profit profil -- consist net incom posit believ share deserv trade
premium ev/sal multipl smid-cap med-tech coverag univers
risk valuat
risk includ failur success execut adopt omnipod type patient potenti manufactur
issu and/or inabl seamlessli ramp product failur advanc pipelin artifici pancrea
product failur bring success drug deliveri partnership commerci increas competit
rate price target histori inc
creat bluematrix
distribut ratings/invest bank servic ib
explan rate
outperform buy expect stock outperform benchmark next month
market perform hold/neutr expect stock perform line benchmark next
under-perform sell expect stock under-perform benchmark next month
degre out-performance under-perform requir warrant outperform under-perform
rate commensur risk profil compani
purpos definit relev benchmark issuer
market capit less billion issuer market
capit billion
